Your browser doesn't support javascript.
BNT162b2 COVID-19 Vaccine Induced Immune Thrombocytopenic Purpura.
Ghosh, A K; Bhushan, S; Lopez, L D R; Sampat, D; Salah, Z; Hatoum, C A.
  • Ghosh AK; Northeast Georgia Medical Center, Gainesville, GA, USA.
  • Bhushan S; Northeast Georgia Medical Center, Gainesville, GA, USA.
  • Lopez LDR; Northeast Georgia Medical Center, Gainesville, GA, USA.
  • Sampat D; Hematology/Oncology Faculty, Northeast Georgia Medical Center, Gainesville, GA, USA.
  • Salah Z; Internal Medicine Faculty, Northeast Georgia Medical Center, Gainesville, GA, USA.
  • Hatoum CA; Internal Medicine Faculty, Northeast Georgia Medical Center, Gainesville, GA, USA.
Case Rep Med ; 2022: 5603919, 2022.
Article in English | MEDLINE | ID: covidwho-1789045
ABSTRACT
Immune thrombocytopenic purpura (ITP) has been reported following vaccinations such as MMR as well as after viral infections such as hepatitis C and HIV. Few case reports have been reported of ITP after COVID-19 infections and COVID-19 vaccines. Herein, we present a patient who presented with severe ITP with a platelet count of 0 after receiving the second dose of the BNT162b2 mRNA COVID-19 vaccine (also known as the Pfizer BioNTech). She subsequently recovered with a prolonged treatment course.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Topics: Vaccines Language: English Journal: Case Rep Med Year: 2022 Document Type: Article Affiliation country: 2022

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Topics: Vaccines Language: English Journal: Case Rep Med Year: 2022 Document Type: Article Affiliation country: 2022